Welcome to the e-CCO Library!

OP028: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohns disease: results from the UNITI-1 and UNITI-2 studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. J. Adedokun*1, Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1, J. Johanns1, L.-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer2, B. Feagan3, W. Sandborn4

Created: Friday, 22 February 2019, 9:49 AM
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targets
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Festen1*, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Yabal1*, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohns disease: a prospective, randomised, multicentre trial (Tailorix)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens*1, S. Vermeire2, G. Lambrecht3, F. Baert4, P. Bossuyt5, M. Nachury6, A. Buisson7, Y. Bouhnik8, J. Filippi9, J. vande Woude10, P. Van Hootegem11, J. Moreau12, E. Louis13, D. Franchimont14, M. De Vos15, F. Mana16, L. Peyrin-Biroulet17, H. Brixi18, M. Allez19, P. Caenepeel20, A. Aubourg21, B. Oldenburg22, M. Pierik23, A. Gils24, S. Chevret25, D. Laharie26

Created: Friday, 22 February 2019, 9:49 AM
OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lewis A.*1, Felice C.1,2, Nihjuis A.1, Iqbal S.1, Mehta S.1, Feakins R.3, Armuzzi A.2, Silver A.1, Lindsay J.4

Created: Wednesday, 20 February 2019, 10:36 AM
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn's disease patients stopping infliximab
Year: 2023
Source: ECCO’23 Copenhagen
Authors: PierreDr., N.(1)*;Huynh-Thu, V.A.(2);Baiwir, D.(3);Mazzucchelli, G.(4);Fléron, M.(3);Trzpiot, L.(4);Eppe, G.(4);Laharie, D.(5);Satsangi, J.(6);Colombel, J.F.(7);Hertervig, E.(8);Meuwis, M.A.(1);Louis, E.(9);
Created: Friday, 14 July 2023, 10:43 AM
OP02: The breastmilk proteomics of women with Inflammatory Bowel Disease (IBD) and its impact on fecal calprotectin and microbiota composition in their babies
Year: 2022
Source: ECCO'22
Authors: Guedelha Sabino, J.(1);Tarassishin, L.(2);Agrawal, M.(3);Eisele, C.(2);Barré, A.(2);Dubinsky, M.(4);Stone, J.(5);Nair, N.(2);Debebe, A.(2);Hawkins, K.(2);Rendon, A.(2);Hu, J.(2);Colombel, J.F.(3);Peter, I.(2);Torres, J.(6);
Created: Friday, 11 February 2022, 3:52 PM
OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Li*1, J. Kuemmerle1

Created: Friday, 22 February 2019, 9:41 AM
OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
Year: 2021
Source: ECCO'21 Virtual
Authors: Irving, P.M.(1,2);Sands, B.E.(3);Hoops, T.(4);Izanec, J.L.(4);Gao, L.L.(4);Gasink, C.(4);Greenspan, A.(4);Allez, M.(5,6);Danese, S.(7);Hanauer, S.B.(8);Jairath, V.(9,10);Kuhbacher, T.(11);Lewis, J.D.(12);Loftus Jr., E.V.(13);Mihaly, E.(14);Panaccione, R.(15);Scherl, E.(16);Shchukina, O.(17);Sandborn, W.J.(18)
Created: Wednesday, 2 June 2021, 4:12 PM
OP03 Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s disease: Long-term follow-up of the LIR!C trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Stevens MD1, L. Haasnoot1, G. D’Haens1, C. Buskens2, E.J. de Groof2, E. Eshuis1, T. Gardenbroef3, B. Mol1, P. Stokkers3, W. Bemelman2, C. Ponsioen1, LIR!C

Created: Thursday, 30 January 2020, 10:12 AM
OP030: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Kobayashi*1, Y. Suzuki2, S. Motoya3, F. Hirai4, H. Ogata5, H. Ito6, N. Sato7, K. Ozaki7, M. Watanabe8, T. Hibi1

Created: Friday, 22 February 2019, 9:49 AM
OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Metwaly A.*1, Butt L.F.1, Waldschmitt N.1, Lagkouvardos I.2, Corraliza A.M.3, Mayorgas A.3, Martinez-Medina M.4, Allez M.5, Panes J.3, Salas A.3, Haller D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory molecules
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Hering1*, C. Gottier1, S. Lang1, B. Becher2, G. Rogler1, M. Scharl1, M. Spalinger1

Created: Thursday, 21 February 2019, 9:14 AM
OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study
Year: 2018
Source: ECCO '18 Vienna
Authors:

N.A. Kennedy1*, G. Heap1,2, B. Hamilton1, G.J. Walker1, C. Bewshea1, S. Bouri3, J. Goodhand1, PANTS Investigator Consortium, T. Ahmad1

Created: Thursday, 21 February 2019, 9:14 AM
OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panés J.*1, D'Haens G.R.2, Higgins P.D.R.3, Mele L.4, Moscariello M.4, Chan G.4, Wang W.4, Niezychowski W.4, Su C.4, Maller E.4

Created: Wednesday, 20 February 2019, 10:36 AM
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Sands B.E.2, Danese S.3, D'Haens G.R.4, Vermeire S.5, Schreiber S.6, Feagan B.7, Reinisch W.8,9, Friedman G.10, Woodworth D.10, Zhang H.10, Lawendy N.10, Niezychowski W.10, Su C.10, Panés J.*11

Created: Wednesday, 20 February 2019, 10:36 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Moens1,2*, K. van Hoeve2,3, E. Humblet4, J.-F. Rahier5, P. Bossuyt6, S. Dewit7, D. Franchimont8, E. Macken9, J. Nijs10, A. Posen11, A. Van Hootegem12, W. Van Moerkercke13, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, De Hertogh G.2, Chen G.3, French D.4, Huntzicker E.4, Van der Aa A.5, Van Kaem T.5, Harrison P.5, Tasset C.5, Galien R.6, Pan Y.4, Feagan B.7, Sandborn W.8

Created: Wednesday, 20 February 2019, 10:36 AM
OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3*, A. Armuzzi4, G.S. Friedman5, M. Moscariello5, N. Lawendy5, R.D. Pedersen5, G. Chan5, C.I. Nduaka5, D. Quirk5, L. Salese5, C. Su5

Created: Thursday, 21 February 2019, 9:14 AM
OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Hansen M.B.3, Feagan B.G.4, Loftus Jr. E.V.5, Rogler G.6, Vermeire S.7, Cruz M.L.2, Yang J.2, Sullivan B.A.2, Reinisch W.*8

Created: Wednesday, 20 February 2019, 10:36 AM